Molecular Partners Ag (MOLN) Prepaid Assets (2020 - 2026)
Molecular Partners Ag's (MOLN) quarterly Prepaid Assets came in at $2.7 million in Q2 2026, down 8.54% year-over-year from $3.0 million in Q2 2025, and up 15.92% quarter-over-quarter from $2.4 million in Q1 2026.
Analysis
Molecular Partners Ag (MOLN) Prepaid Assets (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Prepaid Assets for 7 consecutive years, with $2.7 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Prepaid Assets fell 8.54% year-over-year to $2.7 million in Q2 2026; TTM through Jun 2026 was $2.7 million, a 8.54% decrease from a year earlier, with the FY2025 full-year figure at $2.4 million, down 16.58% from the prior year.
- Prepaid Assets was $2.7 million for Q2 2026 at Molecular Partners Ag, up from $2.4 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $5.0 million in Q3 2022 and troughed at $2.3 million in Q1 2025.
- A 5-year average of $3.5 million and a median of $3.3 million in 2024 frame the typical range for Prepaid Assets.
- Across the five-year window, Prepaid Assets sank 41.32% in 2022 and grew 2.49% in 2026, its largest moves.
- Over 5 years, Prepaid Assets stood at $4.8 million in 2022, then decreased by 14.4% to $4.1 million in 2023, then fell by 29.31% to $2.9 million in 2024, then dropped by 13.83% to $2.5 million in 2025, then grew by 10.09% to $2.7 million in 2026.
- The last three Prepaid Assets figures came in at $2.7 million (Q2 2026), $2.4 million (Q1 2026), and $2.5 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Molecular Partners Ag | 156.54 Mn | 156.54 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.73 Mn |
| Mar 31, 2026 | 2.36 Mn |
| Dec 31, 2025 | 2.48 Mn |
| Sep 30, 2025 | 2.92 Mn |
| Jun 30, 2025 | 2.99 Mn |
| Mar 31, 2025 | 2.30 Mn |
| Dec 31, 2024 | 2.88 Mn |
| Sep 30, 2024 | 3.00 Mn |
| Jun 30, 2024 | 3.44 Mn |
| Mar 31, 2024 | 3.29 Mn |
| Dec 31, 2023 | 4.08 Mn |
| Sep 30, 2023 | 3.99 Mn |
| Jun 30, 2023 | 4.62 Mn |
| Mar 31, 2023 | 3.64 Mn |
| Dec 31, 2022 | 4.76 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Mar 31, 2022 | 4.21 Mn |
| Dec 31, 2021 | 6.21 Mn |
| Sep 30, 2021 | 8.51 Mn |
| Dec 31, 2020 | 1.39 Mn |